A synthetic growth hormone-releasing peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone secretory pathways. Its research landscape includes GH release, pituitary signalling and neuroendocrine regulation.
| Title |
|---|
| 4 vials (15% discount) |
| 8 vials (25% discount) |
| 12 vials (35% disocunt) |
GHRP-2 (Growth Hormone-Releasing Peptide-2), also known as Pralmorelin, is a synthetic hexapeptide investigated for its ability to stimulate growth hormone (GH) secretion. It belongs to the growth hormone secretagogue family and acts primarily through the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor.
GHRP-2 has been investigated in preclinical and human clinical research examining pituitary growth hormone secretion, neuroendocrine regulation and interactions between ghrelin receptor signaling and the growth hormone axis.
Unlike growth hormone-releasing hormone (GHRH) analogues, GHRP-2 activates the ghrelin receptor pathway. Research has demonstrated that these distinct signaling mechanisms can interact to influence growth hormone secretion. Studies have also examined GHRP-2’s effects on appetite and other pituitary hormones, including ACTH, cortisol and prolactin.
GHRP-2 10 mg is presented as an experimental research peptide for laboratory and scientific applications. The stated quantity refers to the amount of peptide contained in the product and should not be interpreted as a recommended human dosage.
Product: GHRP-2
Strength: 10 mg
Alternative name: Growth Hormone-Releasing Peptide-2; Pralmorelin
Category: Growth Hormone
Compound classification: Synthetic hexapeptide; growth hormone secretagogue
Research target: Growth hormone secretagogue receptor (GHS-R1a)
Research focus: Growth hormone secretion, ghrelin receptor signaling, pituitary regulation and GH–IGF-1 axis physiology
Mechanism: Activation of GHS-R1a-mediated signaling pathways that stimulate pituitary growth hormone secretion
Pharmacological profile: Synthetic growth hormone secretagogue investigated in preclinical and human studies, with documented effects on growth hormone secretion and other neuroendocrine pathways
Intended use: Laboratory and research use only
A synthetic analogue of growth hormone-releasing hormone (GHRH) studied through the GHRH receptor and downstream GH/IGF-1 axis. Research areas include endocrine signalling, growth-hormone physiology and metabolic regulation.
A synthetic growth hormone secretagogue peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone signalling pathways. Its research landscape includes GH secretion, neuroendocrine regulation and metabolic signalling.
A two-component research formulation combining a GHRH-pathway analogue with a growth-hormone secretagogue, allowing investigation of two distinct signalling mechanisms converging on the GH axis. Both components and their quantities should remain explicitly identified.
A synthetic fragment derived from the C-terminal region of human growth hormone. Research focuses on the biological properties of this fragment and its relationship to metabolic and GH-associated signalling without representing the complete GH molecule.
A short-acting GHRH-analogue research peptide used to investigate growth-hormone-releasing pathways and GH/IGF-1 signalling. The No-DAC form must be clearly distinguished from albumin-binding CJC-1295 with DAC because their molecular designs are not equivalent.
A growth-hormone secretagogue investigated through ghrelin/GHS receptor signalling and downstream GH physiology. It provides a mechanistically different research route into the GH axis than GHRH analogues such as CJC-1295 and tesamorelin.